AMSTERDAM – NGM Biopharmaceuticals Inc., true to its fascination with the long-lasting effects of gastric bypass surgery and what President Jeff Jonker called the procedure's "fundamental rewiring" of metabolism, honed in on the liver de-fatting feats of its lead candidate, NGM282, during a presentation at the International Liver Conference.